Mission Pharmacal subsidiary ProSolus Inc. said this week that it expanded its manufacturing capabilities and commercialization efforts for transdermal drug delivery technologies.
The Miami-based company, which develops and manufactures transdermal and trans-mucosal drug delivery products, installed a 2nd transdermal production facility in Boerne, Texas. The new location has a larger production line than the Miami site, according to ProSolus, and the 2 sites have a combined annual capacity of more than 100 million patches.
Get the full story at our sister site, Drug Delivery Business News.
The post ProSolus invests in manufacturing capacity for transdermal drug delivery tech appeared first on MassDevice.